Dose range adverse events affected

Patients with known history of tolerance - The mean dose administered to patients in the phase 3 study was 236 units (25% to 75% range, 198 units to 300 units). The dose was divided among the affected muscles. Tailor dosing in initial and sequential treatment sessions to the individual patient based on the patient s head and neck position, localization of pain, muscle hypertrophy, patient response, and adverse event history. 

---